Argus Upgrades McKesson (MCK) to Buy

Argus analyst David Toung upgraded McKesson (NYSE: MCK) from Hold to Buy with a price target of $230.00.

The analyst comments "We are raising our near- and long-term ratings on McKesson Corp. (NYSE: MCK) to BUY from HOLD and setting a price target of $230. The company is boosting profitability and ROE, helped by strong revenue growth in the Medical-Surgical business and improved execution in Prescription Technology Solutions. We also expect it to generate higher volume as the main U.S. distributor of the Moderna and Johnson & Johnson COVID-19 vaccines and ancillary supplies. In addition, the company is exploring the sale of its underperforming UK retail pharmacy business, which could provide resources for new acquisitions."

For an analyst ratings summary and ratings history on McKesson click here. For more ratings news on McKesson click here.

Shares of McKesson closed at $196.00 yesterday.

You May Also Be Interested In

• UPDATE: UBS Upgrades Oshkosh (OSK) to Buy
• Voestalpine AG (VOE:AV) (VLPNY) PT Raised to EUR35 at Deutsche Bank
• La Francaise des Jeux SAEM (FDJ:FP) PT Raised to EUR47.80 at Societe Generale